VAPO - Vapotherm, Inc.

NYSE - NYSE Delayed Price. Currency in USD
16.50
-0.15 (-0.90%)
At close: 4:01PM EST

16.50 0.00 (0.00%)
After hours: 4:57PM EST

Stock chart is not supported by your current browser
Previous Close16.65
Open16.63
Bid0.00 x 1100
Ask19.00 x 1100
Day's Range16.44 - 16.74
52 Week Range14.70 - 22.07
Volume31,724
Avg. Volume71,978
Market Cap285.993M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-47.77
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.67
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Vapotherm® Releases Next Generation of Capital Unit: Precision Flow Hi-VNI™ System

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the release of the next generation of its capital unit: the Precision Flow Hi-VNI system. For this generation of the Precision Flow® system, both the hardware and software have been updated to improve reliability, and to comply with the EMC 4th Edition requirements for medical devices, IEC 60601-1-2:2014. As with all the other models of the Precision Flow system, this generation provides Hi-VNI Technology, the innovation that delivers Mask-Free NIV™ for spontaneously breathing patients.

  • Business Wire2 months ago

    Vapotherm to be Added to the Russell 2000®, 3000® and Microcap® Indexes

    Vapotherm, Inc. (VAPO) announced today that it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after market close on December 21, 2018, as part of Russell’s quarterly addition of companies with recent initial public offerings. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000 Index. Membership in the Russell 2000 Index includes automatic inclusion in the appropriate growth and style indexes, such as the Russell Microcap Index, which represents small-cap and micro-cap stocks.

  • Business Wire2 months ago

    Clinical Study Shows Vapotherm’s New IntellO2™ Module for Precision Flow® System Significantly Improves Maintenance of Premature Neonates in Target Oxygenation Range

    Vapotherm, Inc. today announced the publication of a key prospective, multi-center, controlled, order-randomized crossover trial. The study demonstrates that using the IntellO2 automated oxygen controller module helped clinicians maintain neonates in the physician-prescribed oxygen saturation range significantly better than manual control alone. The results were published by Reynolds and colleagues in the Archives of Disease in Childhood: Fetal and Neonatal Edition, entitled “Randomised crossover study of automated oxygen control for preterm infants receiving nasal High Flow.” The data show that trained staff were able to keep the babies’ oxygen saturation in the target range 49% of the time with manual controls alone.

  • Business Wire3 months ago

    Vapotherm Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the closing of its initial public offering of 4,600,000 shares of common stock, at a price to the public of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 shares of common stock. All of the shares of common stock were offered by Vapotherm.

  • Business Wire3 months ago

    Vapotherm Announces Pricing of Initial Public Offering

    Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the pricing of its initial public offering of 4,000,000 shares of common stock at a price to the public of $14.00 per share.